



Lung Regional Group Meeting
Wednesday 15th September 2010, 2.00pm – 4.00pm
Classroom 1, Fern House
Antrim

In attendance:

Dr Nick Magee – Chair
 Dr Rory Convery
 Ms Yvonne Duff
 Ms Karen Foden
 Ms Mary Ann Conlon
 Ms Louise Kerr
 Ms Michelle Doherty
 Dr John Foster
 Ms Ann Robinson
 Dr Tim Warke
 Dr Wendy Anderson
 Dr Kieran McManus
 Mr Michael Megaw

Apologies:

Dr Jonathan McAleese
 Dr Gerard Daly
 Dr John Lawson
 Mr Paul Scullin
 Ms Jean Maguire
 Dr Dermot Hughes
 Ms Janis McCulla

Summary of key points / outcomes/ action	Identified Party & date
<p>Welcome and introductions Dr Jonathan McAleese welcomed everyone to the meeting and a round of introductions was made.</p> <p>Minutes of previous meeting and matters arising The minutes of the previous meeting were approved as a true and accurate reflection.</p> <p>There were no matters arising</p> <p>Radiotherapy issues <u>Chart and SRT Presentation</u></p> <p>Dr McAleese gave a presentation on Chart and SRT. A copy of the presentation has been included with the minutes.</p> <p>Chemotherapy Issues <u>New drugs business cases</u> Pemetrexed – Dr McAleese outlined that this is now NICE approved and given in the cancer centre. Accessed via single patient application to regional health and social care board.</p> <p>Gefitinib - Dr McAleese outlined that this is now NICE approved.</p>	

Accessed via single patient application to regional health and social care board.

Increased chemotherapy workload

Dr McAleese gave a presentation on increased chemotherapy workload. A copy of the presentation and associated paper will be circulated with the minutes

CaPPs

Mr Megaw gave a presentation outlining a proposed new process for regional network groups getting data from CaPPs. The proposed process is that all queries come directly from the regional group; the queries are then run centrally at the information dept, HSCB, forwarded to trusts for validation and then shared with regional group for analysis and discussion. Following discussion at local lead teams and with some of the lead clinicians and cancer managers, it has been agreed that this process should be clearly documented with a caveat that clinical data remains owned by the trusts and should not be used for any other purpose outside that of regional network discussion.

Date of Next Meeting: